Adial Pharmaceuticals
ADIL
25 hedge funds and large institutions have $674K invested in Adial Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0% more funds holding
Funds holding: 25 → 25 (0)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
69% less capital invested
Capital invested by funds: $2.2M → $674K (-$1.53M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$191K |
| 2 |
Two Sigma Investments
New York
|
+$41.9K |
| 3 |
VF
Virtu Financial
New York
|
+$32.9K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$31.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$25.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$133K |
| 2 |
Millennium Management
New York
|
-$53K |
| 3 |
Charles Schwab
San Francisco,
California
|
-$29K |
| 4 |
Jane Street
New York
|
-$19K |
| 5 |
Renaissance Technologies
New York
|
-$18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Jane Street
New York
| – | -$19K | -22 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$9K | -11 | Closed |
|
28
Morgan Stanley
New York
| – | +$451 | +1 | +100% |
|
ADIL Hedge Fund Activity: Q3 2022 in Review
25 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q3 2022, worth a combined $674K — down 69% from $2.2M a quarter earlier.
Fund positioning in ADIL was balanced in Q3 2022: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $191K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $133K sold.
- 25 institutional investors held Adial Pharmaceuticals (ADIL) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $674K of Adial Pharmaceuticals stock for Q3 2022, down 69% quarter-over-quarter.
- 5 funds opened new Adial Pharmaceuticals positions in Q3 2022 and 5 closed out, a net change of 0 holders.
- The largest Adial Pharmaceuticals buyer in Q3 2022 was Citadel Advisors, an estimated $191K added.
- The largest Adial Pharmaceuticals seller in Q3 2022 was Susquehanna International Group, an estimated $133K sold.
Based on aggregated 13F filings for Q3 2022.